Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Claire N Harrison, DM, FRCP, FRCPath, Richard E Clark, MD, Joseph Chacko, Steven Knapper, DM BMBCh, John Yin, MD, Dragana Milojkovic, PhD, Mira Farquharson, FRCPath, MBChB, MRCP, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Mamta K Garg, MD, FRCP, FRCPath, Christopher Andrews, PhD, Cstat, CSci, Susan M Graham, PhD, Adam J. Mead, M.D., Ph.D.

Blood (2013) 122 (21): 2826.

https://doi.org/10.1182/blood.V122.21.2826.2826

Published: 2013

Journal Articles

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Alan K. Burnett, Nigel H. Russell, Ann E. Hunter, Donald Milligan, Steven Knapper, Keith Wheatley, John Yin, Mary F. McMullin, Sahra Ali, David Bowen, Robert K. Hills

Blood (2013) 122 (8): 1384–1394.

https://doi.org/10.1182/blood-2013-04-496596

Published: 2013

Journal Articles

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Blood (2012) 119 (14): 3361–3369.

https://doi.org/10.1182/blood-2011-09-377044

Published: 2012

Includes: Supplemental data

Journal Articles

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Mike Dennis, Oliver Goodyear, Justin Loke, Nadiria Jilani, Shamyla Siddique, Gordon Ryan, Rehela Khanum, John Snowden, Michael Griffiths, PhD, Nigel H. Russell, MD, John Yin, MD, Charles Crawley, MD, Gordon Cook, MD, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, Paul AH Moss, MD PhD, Ram Malladi, Charles F. Craddock, BM, MRCP, MRCPath

Blood (2011) 118 (21): 324.

https://doi.org/10.1182/blood.V118.21.324.324

Published: 2011

Journal Articles

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

Emmanouil Nikolousis, Sandeep Nagra, Janice Ward, Fiona L Dignan, MD, Bronwen E. Shaw, PhD, MRCP, FRCPath, Simon Littlewood, Jenny Byrne, MD, PhD, Maria Helena Gilleece, MD, FRCPath, MB, BSc, FRCP, Eleni Tholouli, Fiona Clark, Mark Cook, Premini Mahendra, MD, Gordon Cook, MD, John Yin, MD, Nigel H. Russell, MD, Charles Craddock

Blood (2010) 116 (21): 2361.

https://doi.org/10.1182/blood.V116.21.2361.2361

Published: 2010

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Alan Burnett, Robert Hills, MA, MSc, DPhil, Ann Elizabeth Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath, William J. Kell, MD, MB, Keith Wheatley, John Yin, MD, Mary Frances McMullin, MD, Helen Dignum, David Bowen, Nigel H. Russell, MD

Blood (2010) 116 (21): 18.

https://doi.org/10.1182/blood.V116.21.18.18

Published: 2010

Journal Articles

Factors Predicting Long Term Survival after Reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.

Charles F. Craddock, MD, PhD, Sudhir Tauro, MDPhD, Joanne E. Gregory, Laura Buckley, PhD, Janice Ward, BSc(Hons), Panos Kottaridis, MDPhD, Eleni Thelouli, MDPhD, Kirsty Thomson, MDPhD, Donald Milligan, MDPhD, Emma Das-Gupta, MDPhD, Effie Liakpopoulou, MDPhD, John Snowden, MDPhD, John Yin, MDPhD, Andrew Peniket, MDPhD, Mark Cook, MDPhD, Stephen MacKinnon, MDPhD, Nigel H. Russell, MDPhD

Blood (2007) 110 (11): 326.

https://doi.org/10.1182/blood.V110.11.326.326

Published: 2007

Journal Articles

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Ram K. Malladi, MD, Andrew J. Peniket, MD, Timothy James Littlewood, MD, Keiren E. Towlson, MSc SRN, Rachel Pearce, John Yin, MD, Jamie D. Cavanagh, MD, Charles Craddock, MD, Kim H. Orchard, MD, David I. Marks, MD

Blood (2006) 108 (11): 3002.

https://doi.org/10.1182/blood.V108.11.3002.3002

Published: 2006

Journal Articles

Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.

Alan K. Burnett, M. Baccarani, Peter Johnson, John Yin, Andrew Saunders, Nigel Russell, Robert Hills

Blood (2006) 108 (11): 1985.

https://doi.org/10.1182/blood.V108.11.1985.1985

Published: 2006

Journal Articles

The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, RCPath,MRCPI, MA, MB, Robert K. Hills, MA,MSc, DPhil, Nigel H. Russell, MD,FRCP,FRCPath, John Yin, MRCP, MRCPath, Ann Hunter, Dominic Culligan

Blood (2006) 108 (11): 1950.

https://doi.org/10.1182/blood.V108.11.1950.1950

Published: 2006

Journal Articles

A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.

Alan K. Burnett, M. Baccarani, Peter Johnson, John Yin, Andrew Saunders, Nigel Russell, Robert K. Hills

Blood (2006) 108 (11): 425.

https://doi.org/10.1182/blood.V108.11.425.425

Published: 2006

Journal Articles

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

Andreas Reiter, Christoph Walz, Ann Watmore, Claudia Schoch, Ilona Blau, Nick Telford, Shilani Aruliah, John Yin, Danny Vanstraelen, Helen Barker, Peter Taylor, Aisling O’Driscoli, Brigitte Schlegelberger, Ute Berger, Andreas Hochhaus, Rüdiger Hehlmann, Andrew Chase, Nicholas C.P. Cross

Blood (2004) 104 (11): 2963.

https://doi.org/10.1182/blood.V104.11.2963.2963

Published: 2004

Journal Articles

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Blood (2002) 100 (9): 3108–3114.

https://doi.org/10.1182/blood-2002-02-0506

Published: 2002

NARROW

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Factors Predicting Long Term Survival after Reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.

The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.

A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only